Exscientia (NASDAQ:EXAI) Trading Up 4.5%

Exscientia plc (NASDAQ:EXAI)’s share price traded up 4.5% during trading on Wednesday . The stock traded as high as $5.13 and last traded at $5.13. 183,458 shares were traded during mid-day trading, a decline of 71% from the average session volume of 639,510 shares. The stock had previously closed at $4.91.

Analysts Set New Price Targets

Several research firms recently weighed in on EXAI. Barclays reiterated an “equal weight” rating and set a $5.00 target price on shares of Exscientia in a research report on Tuesday, August 13th. TD Cowen reissued a “hold” rating on shares of Exscientia in a research report on Friday, August 9th.

Exscientia Stock Down 1.6 %

The stock has a fifty day moving average of $5.31 and a two-hundred day moving average of $5.33. The company has a quick ratio of 5.93, a current ratio of 5.93 and a debt-to-equity ratio of 0.06. The stock has a market cap of $589.93 million, a price-to-earnings ratio of -3.73 and a beta of 0.85.

Exscientia (NASDAQ:EXAI) last released its quarterly earnings data on Thursday, August 15th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.05). Exscientia had a negative return on equity of 37.56% and a negative net margin of 620.99%. The business had revenue of $5.60 million during the quarter. As a group, analysts predict that Exscientia plc will post -1.25 EPS for the current fiscal year.

Hedge Funds Weigh In On Exscientia

A number of institutional investors and hedge funds have recently bought and sold shares of EXAI. Private Advisor Group LLC lifted its position in shares of Exscientia by 114.3% during the fourth quarter. Private Advisor Group LLC now owns 22,500 shares of the company’s stock worth $144,000 after purchasing an additional 12,000 shares in the last quarter. Jump Financial LLC lifted its holdings in Exscientia by 47.7% in the 4th quarter. Jump Financial LLC now owns 53,755 shares of the company’s stock worth $345,000 after buying an additional 17,355 shares in the last quarter. New Republic Capital LLC acquired a new position in Exscientia in the 4th quarter worth $128,000. Walled Lake Planning & Wealth Management LLC purchased a new position in Exscientia in the 4th quarter valued at about $64,000. Finally, GAMMA Investing LLC grew its stake in shares of Exscientia by 112.1% during the first quarter. GAMMA Investing LLC now owns 4,356 shares of the company’s stock valued at $25,000 after acquiring an additional 2,302 shares in the last quarter. Hedge funds and other institutional investors own 41.58% of the company’s stock.

Exscientia Company Profile

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.